News

Recorlev Safe, Effective Over Long Term for Treatment of Cushing’s, Phase 3 Data Suggest

Long-term treatment with Strongbridge Biopharma‘s Recorlev (levoketoconazole) continues to be well-tolerated and to induce clinically meaningful improvements in endogenous Cushing’s syndrome patients, an extended evaluation of a Phase 3 clinical trial shows. Cushing’s syndrome is a medical condition caused by the excessive production of the hormone cortisol by the…

Targeted Radiosurgery Suitable for Youngsters with Cushing’s Disease and Acromegaly, Study Shows

Stereotactic radiosurgery — a targeted form of radiation therapy — can effectively reduce hormone levels and control tumor progression in children and adolescents with hormone-secreting pituitary adenomas, particularly those with Cushing’s disease and acromegaly, a retrospective study shows. The study, “Outcomes after Gamma knife Stereotactic Radiosurgery in pediatric…

Even in Remission, Cushing’s Patients Have Excess Mortality, Swedish Study Says

Cushing’s disease patients in Sweden have a higher risk of death than the general Swedish population, particularly of cardiovascular complications, and that increased risk persists even in patients in remission, a large nationwide study shows. The study, “Overall and disease-specific mortality in patients with Cushing’s disease: a Swedish nationwide study,”…